Back to today’s briefing

Story perspectives

Eli Lilly's Kisunla Drug Recommended for EU Approval

7/25/2025

44 7

Summary

Story summary

Eli Lilly's Alzheimer’s drug, Kisunla, has received a crucial recommendation for approval from the European Medicines Agency's CHMP, targeting patients with early symptoms and limited ApoE4 gene copies. This marks a significant turnaround after earlier safety concerns led to its rejection. In the U.S., Kisunla is already making waves with broader patient approval.

1 of 1

Story summary

Eli Lilly's Alzheimer’s drug, Kisunla, has received a crucial recommendation for approval from the European Medicines Agency's CHMP, targeting patients with early symptoms and limited ApoE4 gene copies. This marks a significant turnaround after earlier safety concerns led to its rejection. In the U.S., Kisunla is already making waves with broader patient approval.